Will Screening Sales Drive Exact Sciences' Q3 Earnings?

Exact Sciences (EXAS) is slated to report its third-quarter 2024 earnings on Nov. 5.Exact Sciences is a leading cancer diagnostics company, which focuses on the development of new and innovative tests for the prevention of cancer through early detection. The company’s portfolio of FDA-approved flagship cancer screening and diagnostics tests includes Cologuard and Oncotype DX.Exact Sciences has an impeccable earnings surprise history so far. The company reported a loss of 9 cents per share in the second quar ...